Merck Puts MK-0577 Obesity Drug On Hold
After diappointing clinical trials, Merck has put obesity treatment MK-0577 on hold.
The [phase 1] results spurred Merck to initiate a yearlong phase 2 study involving more than 1,600 patients who received placebo or MK-0557. The placebo group lost an average of 4 pounds compared to 7.5 pounds in the MK-0557 group. The difference was statistically significant, but it was not enough to support using the compound as a treatment for obesity, [Steven] Heymsfield said.
Filed under Merck